Effects of denosumab on bone turnover ma
β
Richard Eastell; Claus Christiansen; Andreas Grauer; Stepan Kutilek; Cesar Liban
π
Article
π
2011
π
American Society for Bone and Mineral Research
π
English
β 272 KB
π 1 views
## Abstract Denosumab, a fully human monoclonal antibody to RANKL, decreases bone remodeling, increases bone density, and reduces fracture risk. This study evaluates the time course and determinants of bone turnover marker (BTM) response during denosumab treatment, the percentage of denosumabβtreat